C2i Genomics and Karkinos Healthcare have partnered to co-develop the minimal residual disease market in India.
An artificial intelligence-based model developed by UT Southwestern Medical Center researchers can accurately predict which kidney cancer patients will benefit from anti-angiogenic therapy, a class of treatments that’s only effective in some patients.
